Journal of Forensic and Legal Medicine
Volume 17, Issue 4 , Pages 175-185 , May 2010

Adverse events, toxicity and post-mortem data on duloxetine: Case reports and literature survey

  • Eric L. Vey, MD (Forensic Pathologist)

      Affiliations

    • Erie County Coroner’s Office, Erie, PA, USA
    • Corresponding Author InformationCorresponding author. Address: Erie County Coroner’s Office, 140 West Sixth Street, Erie, PA 16501, USA. Tel.: +1 814 451 6331; fax: +1 814 451 6183.
    • ,
  • Inna Kovelman, DO (Emergency Medicine Resident)

      Affiliations

    • Lehigh Valley Medical Center, Lehigh, PA, USA

Received 23 December 2008 ,Revised 22 September 2009 ,Accepted 4 February 2010.

References 

  1. Sussman N. SNRIs versus SSRIs: mechanisms of action in treating depression and painful physical symptoms. Primary Care Companion J Clin Psychiatry. 2003;5(S7):19–26
  2. Kajdasz DK, Iyengar S, Desaiah D, et al. Duloxetine for the management of diabetic peripheral neuropathic pain: evidence-based findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studies. Clin Ther. 2007;29(Suppl.):2536–2546
  3. Arnold LM, Rosen A, Pritchett YL, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain. 2005;119(1–3):5–15
  4. <http://newsroom.lilly.com/ReleaseDetail.cfm?ReleaseID=305589> [accessed 15.10.08].
  5. Watson WA, Litovitz TL, Rodgers GC, et al. 2004 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. 2005;23(5):589–666
  6. Lai MW, Klein-Schwartz W, Rodgers GC, et al. 2005 Annual report of the American Association of Poison Control Centers’ national poisoning and exposure database. Clin Toxicol (Phila). 2006;44(6–7):803–932
  7. Bronstein AC, Spyker DA, Cantilena LR, Green J, Rumack BH, Heard SE. 2006 Annual report of the American Association of Poison Control Centers’ National Poison Data System (NPDS). Clin Toxicol (Phila). 2007;45(8):815–917
  8. Bronstein AC, Spyker DA, Cantilena Jr LR, Green JL, Rumack BH, Heard SE and American Association of Poison Control Centers. 2007 Annual report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 25th annual report. Clin Toxicol (Phila) 2008;46(10):927–1057.
  9. Anderson D, Reed S, Lintemoot J, et al. A first look at duloxetine (Cymbalta) in a postmortem laboratory. J Anal Toxicol. 2006;30(8):576–580
  10. Baselt RC. Disposition of toxic drugs and chemicals in man, 8th ed. Foster City, California: Biomedical Publications; 2008. p. 617, 1167.
  11. Minyard AN, Nine JS, Smith RK. Identifying baclofen overdose at autopsy. Presented at the 51st annual meeting of the American Academy of Forensic Sciences. Orlando (FL); February 19, 1999.
  12. Menchetti M, Ferrari Gozzi B, Addolorata Saracino M, Mercolini L, Petio C, Augusta Raggi M. Non-fatal overdose of duloxetine in combination with other antidepressants and benzodiazepines. World J Biol Psychiatry. 2008;1–5[Epub ahead of print]
  13. Wong DT, Robertson DW, Bymaster FP, Krushinski JH, Reid LR. LY227942, an inhibitor of serotonin and norepinephrine uptake: biochemical pharmacology of a potential antidepressant drug. Life Sci. 1988;43(24):2049–2057
  14. Preskorn SH. Duloxetine. J Psychiatr Pract. 2004;10(6):375–385
  15. Yang J, Lu X, Bi Y, Qin F, Li F. Chiral separation of duloxetine and its R-enantiomer by LC. Chromatagraphia. 2007;66(5–6):389–393
  16. Fuller RW, Hemrick-Luecke SK, Snoddy HD. Effects of duloxetine, an antidepressant drug candidate, on concentrations of monoamines and their metabolites in rats and mice. J Pharmacol Exp Ther. 1994;269(1):132–136
  17. Product information: Cipla therapeutic index – duloxyl (duloxetine hydrochloride). Mumbai, India: Cipla Ltd.; July, 2008. <http://www.cipladoc.com/therapeutic/admin.php?mode=prod&action=disp&id=446>.
  18. Prescribing information: Cymbalta (duloxetine hydrochloride) delayed-release capsules for oral use. Indianapolis (IN): Eli Lilly and Company; 2004, 2008 [revised 11.08.08].
  19. Suri A, Reddy S, Gonzales C, Knadler MP, Branch RA, Skinner MH. Duloxetine pharmacokinetics in cirrhotics compared with healthy subjects. Int J Clin Pharmacol Ther. 2005;43(2):78–84
  20. Skinner MH, Kuan HY, Skerjanec A, et al. Effect of age on the pharmacokinetics of duloxetine in women. Br J Clin Pharmacol. 2004;57(1):54–61
  21. Lantz RJ, Gillespie TA, Rash TJ, et al. Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab Dispos. 2003;31:1142–1150
  22. Chan C, Yeo KP, Pan AX, Lim M, Knadler MP, Small DS. Duloxetine pharmacokinetics are similar in Japanese and Caucasian subjects. Br J Clin Pharmacol. 2007;63(3):310–314
  23. Chalon SA, Granier LA, Vandenhende FR, et al. Duloxetine increases serotonin and norepinephrine availability in healthy subjects: a double-blind, controlled study. Neuropsychopharmacology. 2003;28(9):1685–1693
  24. Lott RS, Baker DE. Duloxetine: a new antidepressant. Adv Pharm. 2003;1(3):228–241
  25. Cruz MP, Gonzales ME, Jacobs J, LaFave MC. Duloxetine HCL (Cymbalta) for the treatment of depression, neuorpathic pain, fibromyalgia, and stress urinary incontinence. PT. 2006;31(2):84–97
  26. Bymaster FP, Lee TC, Knadler MP, Detke MJ, Iyengar S. The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression. Curr Pharm Des. 2005;11(12):1475–1493
  27. Ogden CL, Fryar CD, Carroll MD, Flegal KM. Mean body weight, height, and body mass index, United States 1960–2002. Adv Data. 2004;347:1–17
  28. Sharma A, Goldberg MJ, Cerimele BJ. Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J Clin Pharmacol. 2000;40(2):161–167
  29. Ma N, Zhang BK, Li HD, et al. Determination of duloxetine in human plasma via LC/MS and subsequent application to a pharmacokinetic study in healthy Chinese volunteers. Clin Chim Acta. 2007;380(1–2):100–105
  30. Kavanagh RE. New drug application: clinical pharmacology and biopharmaceutics review (#2), part 1– NDA21-427, Cymbalta® (Duloxetine HCl) EC capsules. Office of Clinical Pharmacology and Biopharmaceutics/Division of Pharmaceutical Evaluation I, Center for Drug Evaluation and Research, Food and Drug Administration: Approval Package for Application Number 21-427. Washington, DC; August 23, 2002. <http://www.fda.gov/cder/foi/nda/2004/021427_s000_Cymbalta.htm> [accessed 23.10.08].
  31. Deuschle M, Mase E, Zink M. Dyskinesia during treatment with duloxetine. Pharmacopsychiatry. 2006;39(6):237–238
  32. Loper T, Touchet B. An acute attack of porphyria in a patient taking duloxetine. Psychosomatics. 2007;48(2):179–180
  33. Ezzo DC, Patel PN. Facial flushing associated with duloxetine use. Am J Health Syst Pharm. 2007;64(5):495–496
  34. Oulis P, Masdrakis VG, Karakatsanis NA, Karapoulios E, Kouzoupis AV, Soldatos CR. Duloxetine-induced cutaneous adverse reaction. J Clin Psychopharmacol. 2008;28(1):104–105
  35. De Las Cuevas C, Sanz EJ. Duloxetine-induced excessive disturbing and disabling yawning. J Clin Psychopharmacol. 2007;27(1):106–107
  36. Balhara Y, Sagar R, Varghese ST. Bleeding gums: duloxetine may be the cause. J Postgrad Med. 2007;53(1):44–45
  37. Espeleta VJ, Moore WH, Kane PB, Baram D. Eosinophilic pneumonia due to duloxetine. Chest. 2007;131(3):901–903
  38. Bergman BR, Reynolds HR, Skolnick AH, Castillo D. A case of apical ballooning cardiomyopathy associated with duloxetine. Ann Int Med. 2008;149(3):218–219
  39. CYMBALTA® (duloxetine hydrochloride) delayed-release capsules. Product labeling. Indianapolis (IN): Eli Lilly and Company; 2005.
  40. Hanje AJ, Pell LJ, Votolato NA, Frankel WL, Kirkpatrick RB. Case report: fulminant hepatic failure involving duloxetine hydrochloride. Clin Gastroenterol Hepatol. 2006;4(7):912–917
  41. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245
  42. Danan G, Benichou C. Causality assessment of adverse reactions to drugs. I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993;46:1323–1330
  43. Maria VAJ, Victorino RMM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology. 1997;26:664–669
  44. Eisenberg P. Safety data on Cymbalta® (duloxetine hydrochloride) – hepatic effects. Dear Health Care Professional letter. Indianapolis (IN): Lilly Research Laboratories; 2005;
  45. <http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm151091.htm>. #Cymbalta [accessed 25.11.08].
  46. <http://www.fda.gov/Safety/MedWatch/SafetyInformation/Safety-RelatedDrugLabelingChanges/ucm123474.htm> [accessed 25.11.08].
  47. Schulz M, Schmoldt A. Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics. Pharmazie. 2003;58(7):447–474
  48. Pélissier-Alicot AL, Gaulier JM, Champsaur P, Marquet P. Mechanisms underlying postmortem redistribution of drugs: a review. J Anal Toxicol. 2003;27(8):533–544
  49. Cook DS, Braithwaite RA, Hale KA. Estimating antemortem drug concentrations from postmortem blood samples: the influence of postmortem redistribution. J Clin Pathol. 2000;53(4):282–285
  50. Baselt RC. Disposition of toxic chemicals in man. 8th ed.. Foster City, CA: Biomedical Publications; 2008;p. 134
  51. Chong CF, Wang TL. An unusual presentation of baclofen overdose. Emerg Med J. 2005;22(9):673–674
  52. Wall GC, Wasiak A, Hicklin GA. An initially unsuspected case of baclofen overdose. Am J Crit Care. 2006;15(6):611–613

PII: S1752-928X(10)00005-3

doi: 10.1016/j.jflm.2010.02.002

Journal of Forensic and Legal Medicine
Volume 17, Issue 4 , Pages 175-185 , May 2010

Article Tools

* Image Usage & Resolution